Please ensure Javascript is enabled for purposes of website accessibility

Why Infinity Pharmaceuticals Blasted 38% Higher Today

By Eric Volkman – Aug 2, 2021 at 6:07PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

A big investment bank took a new and very bullish view on the stock.

What happened

Clinical-stage biotech Infinity Pharmaceuticals (NASDAQ: INFI) had a big and bright Monday, with its stock closing the session more than 38% higher. The rocket that lifted it was ignited by a prominent investment bank's upgrade, the latest in a series of analyst upgrades for the stock.

So what

The newest bull for Infinity is Anupam Rama at JPMorgan Chase unit JPMorgan. The prognosticator upped his recommendation on Infinity stock to overweight (buy) from his previous assessment of neutral, with a price target of $6 per share. That was nearly triple Friday's closing price for the developer of novel cancer treatments.

Piggy bank with stethoscope.

Image source: Getty Images.

That was far from the first analyst upgrade to come in the wake of Infinity's release last week of clinical trial data for its oncology drug candidate eganelisib. The company divulged that in a phase 2 trial, eganelisib was found to be rather efficacious when used in combination therapy for urothelial cancer.

Specifically, Infinity wrote in a press release, "the data showed that eganelisib increased overall survival in patients with metastatic urothelial cancer and prolonged progression free survival in patients with TNBC."

However, in another trial examining it as a treatment for triple-negative breast cancer -- also as part of combination therapy -- the results were a bit less impressive.

Now what

Following the news about the urothelial cancer trial results, Wells Fargo analyst Nick Abbott moved his recommendation on Infinity from equal weight (neutral) to overweight (buy), and set a hefty price target of $14. Piper Sandler's Edward Tenthoff maintained his overweight recommendation while upping his price target from $7 to $8.

Infinity Pharmaceuticals is a hot biotech issue at the moment. If eganelisib continues to perform well in clinical trials, there's probably more heat to come.

Eric Volkman has no position in any of the stocks mentioned. JPMorgan Chase is an advertising partner of The Ascent, a Motley Fool company. Wells Fargo is an advertising partner of The Ascent, a Motley Fool company. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 11/30/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.